Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer

Panagiotis A. Konstantinopoulos(Dana-Farber Cancer Institute), Stephen A. Cannistra(Beth Israel Deaconess Medical Center), Srisowmya Sanisetty(Beth Israel Deaconess Medical Center), Jonathan L. Hecht(Beth Israel Deaconess Medical Center), Nancy Francoeur(Icahn School of Medicine at Mount Sinai), Dimitrios Spentzos(Beth Israel Deaconess Medical Center), Elena Fountzilas(St. Luke's Hospital), Alexandros Grammatikos(Beth Israel Deaconess Medical Center)
Cancer Research
June 15, 2011
10.1158/0008-5472.can-10-4668
Cited by 266

Related Papers

COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets
|Nature|2021|879
Review of precision cancer medicine: Evolution of the treatment paradigm
|Cancer Treatment Reviews|2020|747
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
|Oncotarget|2016|616
A single-cell landscape of high-grade serous ovarian cancer
|Nature Medicine|2020|522
Gene Expression Profile of <i>BRCA</i>ness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
|Journal of Clinical Oncology|2010|488